Novo Nordisk and Abbott announce digital diabetes tie-up
Pharmaphorum Media Limited | February 21, 2019
Novo Nordisk and devices firm Abbott have announced a partnership that aims to make diabetes management easier by linking technologies such as continuous glucose monitoring with connected insulin pens. The non-exclusive deal will integrate dose data from Novo’s pre-filled connected pens directly into digital health tools compatible with Abbott’s FreeStyle Libre system – including a mobile app and cloud-based system. The companies said that by integrating the products, healthcare professionals, caregivers and people with diabetes will be able to view glucose and insulin data together.
This will help them with their treatment decisions and have a more “meaningful and productive conversation” about health outcomes. Anders Dyhr Toft, corporate vice president, commercial innovation at Novo Nordisk, said: “Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors. “Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient’s individual diabetes management and can help people with diabetes feel more confident about their treatment.”